Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.

其他相關內容

2025/12/18 文章

In-Vivo CAR-T From Concept to Clinic – What It Will Take to Win the “Age of In-Vivo”

...

報告